Creating 100% Pathogen Free Environments

Oct. 1, 2008 – Medizone International, Inc. (MZEI.PK) Announces Hospital Sterilization Initiative

Medizone International, Inc. (MZEI.PK) Announces Hospital Sterilization Initiatiative

SAN FRANCISCO,CALIFORNIA. October 1, 2008 - Medizone International, Inc. (Pink Sheets: MZEI)) announces a new strategic thrust pursuing the development of a novel ozone-based technology which will offer a safe, inexpensive, extremely effective means of disinfecting medical facilities of all bacteria, fungi and viruses known to cause hospital-derived infections. Since this technology is not considered a medical treatment or a diagnostic, its' developmental pathway will not be subject to regulatory review nor the requirement for a lengthy clinical trial process. Medizone Board member and Project Director, Dr. Michael E. Shannon stated, “Our focus with this initiative will be on peer reviewed science and engineering excellence. Hospital-derived infections have grown to immense proportions worldwide with several recently published studies indicating that the incidence of such infections has climbed dramatically over the last ten years in the US with the mortality rate more than doubling during the same period despite increased public health efforts to control the situation. At present, there is no known means to effectively eliminate many of the highly virulent bacterial contaminants now commonly found in critical hospital treatment areas such as surgical suites, emergency rooms and intensive care units. Yet there clearly appears to be an answer. Based on independent research recently conducted at an internationally-renowned institute, ozone-based technology has been shown to effectively eradicate 99.99% of the 6 most serious bacterial agents including C-difficile and Methecillin-Resistant Staphylococcus Aureus (MRSA) within 90 minutes, with the hospital space almost immediately re-usable using a second newly-developed technology. In effect, virtually any contaminated facility may be fully sterilized and returned to service in 2 hours or less. Such a development should have a monumental impact on health care systems globally.”

Mr. Edwin Marshall, Chairman and CEO of Medizone International stated, “with Dr. Shannon’s leadership in this exciting new initiative, we anticipate being fully commercialized within 18 months. The anticipated revenue generated will fund advanced efforts in developing bio-terrorism counter-measures, an area of enormous potential for this technology, as well as funding a new focus on our work in the treatment of Hepatitis C”.

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to decontaminate and sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

For more information contact:
Medizone International, Inc.
(415) 868-0300
Web site:


Medizone International, Inc. (MZEI.OB)

4000 Bridgeway, Suite 401,
Sausalito, CA 94965

Telephone: 415-331-0303


Investor Relations:

John Pentony

Investor Relations,
Medizone International, Inc.

Telephone: (415) 331-0202


Media Contact:

Gary Hanauer

Media Relations,
Medizone International, Inc.

Telephone: (510) 686-1238